retatrutide parkinson disease clinical trial retatrutide parkinson's clinical trial Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update Retatrutide Shows 28.3% Weight Loss

Generally speaking, GLP-1 may be used to lose a few pounds or over 100 pounds

The side effects that dominated early treatment nausea, constipation, fatigue are usually well-managed or absent

Liraglutide increases cyclic adenosine monophosphate (cAMP) and -catenin levels, boosting osteogenic activity [112]

While studies in mice indicate the potential direct benefits of GLP-1 on the skeletal muscle and bone, human data supporting this hypothesis are absent owing to the absence of GLP-1 receptors in the human skeletal muscle, implying that any effects on muscles are likely indirect [114]

doi: 10.1016/j.jhsa.2006.03.022

Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K